These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33815827)

  • 21. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study.
    Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Ochiai K; Nakayama D
    Cardiol Ther; 2020 Jun; 9(1):167-188. PubMed ID: 32152956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
    Miller L; Ferreira JA; Tucker C
    J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.
    Edwards G; Roman C; Jithoo R; Mitra B
    Trauma Case Rep; 2018 Feb; 13():46-49. PubMed ID: 29644298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report.
    Baule A; Cabigiosu F; Zanda B; Sanna A; Mongili C; Manca A
    J Vasc Interv Neurol; 2018 Nov; 10(2):15-17. PubMed ID: 30746004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.
    Tralhão A; Aguiar C; Ferreira J; Rebocho MJ; Santos E; Martins D; Neves JP
    Thromb J; 2017; 15():23. PubMed ID: 28878572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [More safe anticoagulant treatment - use of idarucizumab (Praxbind®): case reports from RE-VERSE AD study and clinical practice].
    Tuček D; Veleta T; Havrda M
    Vnitr Lek; 2018; 64(3):309-313. PubMed ID: 29766734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world experience with reversal of dabigatran by idarucizumab.
    Haastrup SB; Hellfritzsch M; Nybo M; Hvas AM; Grove EL
    Thromb Res; 2021 Jan; 197():179-184. PubMed ID: 33227654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
    Vornicu O; Larock AS; Dincq AS; Douxfils J; Dogné JM; Mullier F; Lessire S
    Expert Opin Biol Ther; 2017 Oct; 17(10):1275-1296. PubMed ID: 28728489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
    Crespo-Leiro MG; López-Vilella R; López Granados A; Mirabet-Pérez S; Díez-López C; Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Rangel-Sousa D; Blasco-Peiró T; de la Fuente-Galán L; Díaz-Molina B; Zatarain-Nicolás E; Carrasco Ávalos F; Almenar-Bonet L
    Clin Transplant; 2019 Dec; 33(12):e13748. PubMed ID: 31670852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The first experience with dabigatran antidote in the University Hospital Pilsen].
    Šlechtová J; Hajšmanová Z; Lavičková A; Šigutová P
    Cas Lek Cesk; 2016; 155(8):442-444. PubMed ID: 28098476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting.
    Gendron N; Chocron R; Billoir P; Brunier J; Camoin-Jau L; Tuffigo M; Faille D; Teissandier D; Gay J; de Raucourt E; Suner L; Bonnet C; Martin AC; Lasne D; Ladhari C; Lebreton A; Bertoletti L; Ajzenberg N; Gaussem P; Morange PE; Le Cam Duchez V; Viallon A; Roy PM; Lillo-le Louët A; Smadja DM
    Front Med (Lausanne); 2020; 7():599626. PubMed ID: 33392223
    [No Abstract]   [Full Text] [Related]  

  • 39. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.
    Fanikos J; Murwin D; Gruenenfelder F; Tartakovsky I; França LR; Reilly PA; Kermer P; Wowern FV; Lane DA; Butcher K
    Thromb Haemost; 2020 Jan; 120(1):27-35. PubMed ID: 31470445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.